Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Michelle Petri(Johns Hopkins University), Marta Mosca(University of Pisa), Kenneth Kalunian(University of California, San Diego), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Conor J McVeigh(Eli Lilly (United States)), Eric F. Morand(Novartis (Switzerland)), Ian N Bruce(University of Manchester), Bochao Jia(Eli Lilly (United States)), Youna Zhao(Eli Lilly (United States)), Gabriella Meszaros(Eli Lilly (United States)), Thomas Dörner(German Rheumatism Research Centre), Lu Zhang(Xiamen University), Maria Silk(Eli Lilly (United States)), Christina Dickson(Eli Lilly (United States)), Mario H. Cardiel(Universidad de Morelia)
Cited by 164
Related Papers
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
|Nature Biotechnology|2006|2.2k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840